AceCys 600 mg powder for oral solution Bulharsko - bulharčina - Изпълнителна агенция по лекарствата

acecys 600 mg powder for oral solution

Химакс Фарма ЕООД - Ацетилцистеин - 600 mg powder for oral solution

Acc Syrup 20 mg/ml oral solution Bulharsko - bulharčina - Изпълнителна агенция по лекарствата

acc syrup 20 mg/ml oral solution

hexal ag - Ацетилцистеин - 20 mg/ml oral solution

Acc Honey aNd lemon 600 mg powder for oral solution Bulharsko - bulharčina - Изпълнителна агенция по лекарствата

acc honey and lemon 600 mg powder for oral solution

hexal ag - Ацетилцистеин - 600 mg powder for oral solution

Acc 200 mg powder for oral solution Bulharsko - bulharčina - Изпълнителна агенция по лекарствата

acc 200 mg powder for oral solution

hexal ag - Ацетилцистеин - 200 mg powder for oral solution

Ultomiris Európska únia - bulharčina - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - Хемоглобинурия, пароксизма - Селективни имуносупресори - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Vyvgart Európska únia - bulharčina - EMA (European Medicines Agency)

vyvgart

argenx - efgartigimod alfa - myasthenia gravis - Имуносупресори - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.